- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Groton Medtech Firm Raises $3.5M for Cancer-Focused AI Platform
Neosoma's cloud-based software analyzes tumor changes to aid treatment decisions.
Apr. 1, 2026 at 9:33pm
Got story updates? Submit your updates here. ›
Groton-based medical technology company Neosoma has raised $3.52 million in venture capital toward its goal of $5.8 million. Neosoma uses AI software to create a 3D analysis of cancerous tumors, providing physicians with information about how a patient's tumor is changing to aid treatment decisions.
Why it matters
Neosoma's technology aims to improve cancer care by giving doctors a more detailed, data-driven view of how tumors are responding to treatment over time. This could lead to more personalized and effective treatment plans for patients.
The details
Neosoma's equity raise included 52 investors, according to an SEC filing. The company was founded in 2019 by CEO Ken Kolodziej and Chief Medical Officer Dr. Aly Abayazeed. Neosoma's cloud platform, Neosoma Brain Mets, gained clearance from the FDA in December, allowing the company to market the product in the U.S. Neosoma is also seeking clearance to sell in Europe this year.
- Neosoma was founded in 2019.
- Neosoma Brain Mets gained FDA clearance in December 2025.
- Neosoma is seeking European clearance in 2026.
The players
Neosoma
A medical technology company based in Groton, Massachusetts that uses AI software to analyze cancerous tumors and aid treatment decisions.
Ken Kolodziej
The CEO and co-founder of Neosoma.
Dr. Aly Abayazeed
The Chief Medical Officer and co-founder of Neosoma.
What they’re saying
“Every treatment decision is based on the way a tumor changes between MRIs. Everything we've done up until now has set the stage for this next funding round.”
— Ken Kolodziej, CEO, Neosoma
What’s next
Neosoma is seeking to gain clearance to sell its Neosoma Brain Mets platform in Europe this year.
The takeaway
Neosoma's AI-powered tumor analysis technology has the potential to transform cancer care by providing physicians with more detailed, data-driven insights to guide personalized treatment plans for patients.
